INSM

INSM

USD

Insmed Incorporated Common Stock

$182.770-2.510 (-1.355%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$185.280

Hoch

$187.880

Tief

$182.580

Volumen

1.57M

Unternehmensfundamentaldaten

Marktkapitalisierung

39.0B

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

2.46M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $60.4Aktuell $182.770Hoch $197.08

Ähnliche Nachrichten

Analyst Upgrades

Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $217

Wells Fargo analyst Tiago Fauth maintains Insmed with a Overweight and raises the price target from $171 to $217.

Mehr anzeigen
Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $217
Analyst Upgrades

Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $225

Goldman Sachs analyst Andrea Tan maintains Insmed with a Buy and raises the price target from $196 to $225.

Mehr anzeigen
Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $225
Analyst Upgrades

UBS Maintains Buy on Insmed, Raises Price Target to $223

UBS analyst Trung Huynh maintains Insmed with a Buy and raises the price target from $194 to $223.

Mehr anzeigen
UBS Maintains Buy on Insmed, Raises Price Target to $223
Analyst Upgrades

RBC Capital Maintains Outperform on Insmed, Raises Price Target to $215

RBC Capital analyst Leonid Timashev maintains Insmed with a Outperform and raises the price target from $139 to $215.

Mehr anzeigen
RBC Capital Maintains Outperform on Insmed, Raises Price Target to $215
Analyst Upgrades

B of A Securities Maintains Buy on Insmed, Raises Price Target to $187

B of A Securities analyst Jason Zemansky maintains Insmed with a Buy and raises the price target from $142 to $187.

Mehr anzeigen
B of A Securities Maintains Buy on Insmed, Raises Price Target to $187
Analyst Upgrades

UBS Maintains Buy on Insmed, Raises Price Target to $194

UBS analyst Trung Huynh maintains Insmed with a Buy and raises the price target from $140 to $194.

Bleiben Sie auf dem Laufenden

Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.